Board Recruitment Announcement
Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the [...]
Somatuline Motorized Delivery Device – Press Release
Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for [...]
Caring Virtually: A Virtual Care Oncology Patient Study
I am writing to you as the co-Principal Investigator on CaringVirtually, a virtual care oncology patient study, requesting your support in sharing information about this study with your patient [...]
CNETS Board Member Awareness
CNETS Board Member Awareness Patient Education and Fundraising A core function of CNETS is to offer the Canadian neuroendocrine cancer community useful, [...]
QEII Times & Chronicle Herald Publishes Articles on NET Cancer & Ga68-Dotatate
CNETS participates in and supports QEII fall publication on Ga68/NETSPOT accessibility in Atlantic Canada. The QEII Times and the Chronicle Herald published a two-page spread on Saturday, October 16, [...]
Les Cancers Endocriniens, published in Le Médecin du Québec
Les Cancers Endocriniens, published in Le Médecin du Québec, October 2021 Dre. Cynthia Landry is a primary care physician in Châteauguay, Quebec, working as an emergency physician [...]
From Gallstones to Cancer: A Mother’s Journey with NETs
Our amazing Hamilton/Halton/Niagara NET Support Group Leader, Vannesa Mann, shares her inspirational story! Zoomer | September 10th, 2021 For people with neuroendocrine tumours, early diagnosis and timely [...]
Pewter Zebra Keyfobs/Pendants
Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and [...]
Temozolomide Access in Ontario
CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]
Lutathera Funded in Saskatchewan
As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]